Manufacturing support for nonclinical drug development Materials intended for nonclinical studies must be suitable for their intended use. Depending on the study and applicable requirements, this may involve defining formulation specifications, documenting manufacturing activities and characterizing relevant product attributes. Good Laboratory Practice (GLP) establishes quality principles for the planning, performance, monitoring, recording and reporting of applicable nonclinical safety studies. GLP compliance does not automatically apply to every manufacturing activity associated with those studies. The manufacturing and documentation requirements for nonclinical test materials therefore need to be established in relation to the intended study, applicable regulatory framework and responsibilities of the organizations involved. Key considerations for nonclinical manufacturing Manufacturing a formulation for nonclinical evaluation requires an understanding of the active pharmaceutical ingredient (API), the dosage form and the characteristics that may influence study results. Consideration Development relevance Formulation composition Defining the API, polymer materials and other components used in the test material. Manufacturing documentation Recording relevant materials, processing conditions and manufacturing activities. Batch consistency Evaluating variation in relevant product attributes between manufactured batches. API integrity Assessing whether processing and formulation conditions affect molecular quality attributes. Product characterization Measuring attributes relevant to the intended nonclinical evaluation. Traceability Maintaining appropriate records of materials, batches and associated analytical results. The extent of testing and documentation depends on the intended use of the material. Requirements should be defined for the specific development program rather than assuming that one approach is appropriate for every nonclinical study. Nonclinical manufacturing for long-acting injectables Polymer-based sustained-release formulations introduce additional considerations because the delivery system influences how the API is incorporated and released. For microsphere formulations, relevant attributes may include particle size distribution, morphology, drug loading and in vitro release behavior. These characteristics can be affected by polymer composition and manufacturing conditions. During long-acting injectable development, understanding these relationships helps determine which formulation and process attributes should be monitored when preparing material for nonclinical evaluation. For peptides and biologics, molecular integrity also requires attention. Processing conditions and the environment within a biodegradable polymer matrix may influence API stability, making molecule-specific characterization important. Formulation and process consistency Manufacturing consistency begins with a formulation and process that are sufficiently understood for the intended development stage. Through pharmaceutical formulation development, candidate compositions can be investigated for API compatibility, drug loading, stability and release characteristics. Process development then evaluates how manufacturing parameters influence these attributes and whether the process can produce material reproducibly. For nonclinical applications, relevant manufacturing parameters and product characteristics should be documented so that differences between batches can be assessed where necessary. A formulation prepared for early feasibility work may require further development before it is suitable for a specific nonclinical study. The required level of process understanding and control depends on the study objectives and applicable requirements. Discuss your nonclinical manufacturing requirements Contact Innocore Analytical characterization of nonclinical materials Analytical testing provides information about the identity, composition and relevant quality attributes of manufactured test materials. Depending on the API and dosage form, characterization may include drug content, molecular integrity, physical properties and in vitro release behavior. The analytical strategy should reflect the questions that need to be answered during nonclinical development. Through analytical development, methods can be established and evaluated for their intended application. Appropriate documentation of analytical procedures and results helps support the interpretation of material characteristics and comparisons between batches. In vitro release data can provide useful information about formulation behavior, but should not be assumed to predict in vivo release without supporting product-specific evidence. Connecting nonclinical development with later manufacturing Nonclinical manufacturing activities can generate valuable knowledge about formulation behavior, processing conditions and product quality. As a development program progresses, this information may support further process optimization, additional analytical work and preparation for subsequent manufacturing activities. Technology transfer can help communicate relevant formulation, process and analytical knowledge to a receiving manufacturing environment. Additional development, qualification or validation activities may be required depending on the intended manufacturing stage. Innocore’s broader CDMO services connect formulation development, analytical characterization and process knowledge within a coordinated development approach. Frequently asked questions about GLP manufacturing What is GLP manufacturing? + The term GLP manufacturing is sometimes used for manufacturing activities associated with nonclinical studies. Strictly speaking, Good Laboratory Practice is a quality system for applicable nonclinical safety studies rather than a general pharmaceutical manufacturing standard. The requirements for producing study materials must be determined separately. What is the difference between GLP and GMP? + GLP addresses the conduct and documentation of applicable nonclinical safety studies. Good Manufacturing Practice (GMP) establishes requirements for pharmaceutical manufacturing and quality control. The applicable requirements depend on the activity, product and development stage. Why is batch characterization important for nonclinical studies? + Characterization provides information about the material used in a study. For sustained-release formulations, relevant attributes may include API content, molecular integrity, physical characteristics and release behavior. Can material produced during early development be used in nonclinical studies? + Potentially, depending on the study and applicable requirements. Material suitability must be assessed against the intended use, including relevant quality attributes, documentation and manufacturing controls. Discuss your nonclinical manufacturing requirements Preparing polymer-based sustained-release formulations for nonclinical evaluation requires coordination between formulation science, process development, analytical characterization and appropriate documentation. Contact Innocore to discuss your API, intended nonclinical application and the manufacturing requirements of your development program. Contact Innocore